1 |
Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types / 相同組換え修復欠損のがん横断的バイオマーカーとしての有用性Takamatsu, Shiro 24 November 2022 (has links)
京都大学 / 新制・課程博士 / 博士(医学) / 甲第24280号 / 医博第4896号 / 新制||医||1061(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 森田 智視, 教授 松田 道行, 教授 波多野 悦朗 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM
|
2 |
A Risk Model Developed Based on Homologous Recombination Deficiency Predicts Overall Survival in Patients With Lower Grade GliomaPeng, Hao, Wang, Yibiao, Wang, Pengcheng, Huang, Chuixue, Liu, Zhaohui, Wu, Changwu 20 October 2023 (has links)
The role of homologous recombination deficiency (HRD) in lower grade glioma (LGG) has not
been elucidated, and accurate prognostic prediction is also important for the treatment and
management of LGG. The aim of this study was to construct an HRD-based risk model and to
explore the immunological and molecular characteristics of this risk model. The HRD score
threshold = 10 was determined from 506 LGG samples in The Cancer Genome Atlas cohort
using the best cut-off value, and patients with highHRDscores had worse overall survival. A total
of 251 HRD-related genes were identified by analyzing differentially expressed genes, 182 of
which were associated with survival. A risk score model based on HRD-related genes was
constructed using univariate Cox regression, least absolute shrinkage and selection operator
regression, and stepwise regression, and patients were divided into high- and low-risk groups
using the median risk score. High-risk patients had significantly worse overall survival than lowrisk
patients. The risk model had excellent predictive performance for overall survival in LGG and
was found to be an independent risk factor. The prognostic value of the riskmodel was validated
using an independent cohort. In addition, the risk score was associated with tumor mutation
burden and immune cell infiltration in LGG. High-risk patients had higher HRD scores and “hot”
tumor immune microenvironment, which could benefit from poly-ADP-ribose polymerase
inhibitors and immune checkpoint inhibitors. Overall, this big data study determined the
threshold of HRD score in LGG, identified HRD-related genes, developed a risk model
based on HRD-related genes, and determined the molecular and immunological
characteristics of the risk model. This provides potential new targets for future targeted
therapies and facilitates the development of individualized immunotherapy to improve prognosis.
|
Page generated in 0.1125 seconds